Half-life

2.7 h

Tmax

1 h

Category

peptide

Also known as: bremelanotide

PT-141 (bremelanotide) is a melanocortin receptor agonist with improved selectivity for MC4R over MC1R compared with Melanotan II, reducing the melanogenic side effect while preserving effects on sexual response pathways. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. Administered subcutaneously via auto-injector, it has a half-life of approximately 2 hours. Common side effects include nausea, flushing, and transient blood pressure elevation. Tracking dose timing, response, and side effects is recommended for individuals using this compound.

Mechanism

PT-141 (bremelanotide) is a melanocortin receptor agonist acting centrally, notably at MC4 receptors, and is associated in research with effects on sexual arousal that are distinct from vascular-acting agents.

Research summary

The compound bremelanotide is FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in certain premenopausal women, based on clinical trials. Use outside the approved indication and via unregulated products is common but not supported by that approval.

Reported side effects

Reported effects include nausea, flushing, headache, and transient increases in blood pressure with decreases in heart rate. Prescribing information notes cautions including uncontrolled hypertension and cardiovascular disease. This is not a complete safety profile.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Vyleesi prescribing information · FDA prescribing information (2019)Half-life about 2.7 h; median Tmax about 1 h.

References

Bremelanotide PK/PDDOI: 10.1002/jcph.1118

TrackPep on seurantasovellus. Se tallentaa tekemäsi kirjaukset eikä koskaan suosittele tai laske määriä.